Telemedicine

On August 19, 2024, the Agenda for the meeting of the Board of Danish Regions was published. One of the themes to be discussed during the meeting was the Danish Regions consultation response regarding the Health Structure Commission's report. The meeting was held on August 22, 2024.

On June 10, 2024, the National Agency for Regional Health Services (AGENAS) announced an online public consultation on the draft of the “Guidelines on the Evolutionary Pathway of Medical Systems for Telemonitoring”.

On April 25, 2024, the Ministry of Labor, Health, and Solidarity published an Order in the Official Journal of the French Republic setting the tariffs for digital medical devices with therapeutic functions covered within the early digital support (PECAN) scheme. The tariff for the manufacturer will include an initial lump sum of €435 per patient billable for up to 3 months and a subsequent monthly package of €38.30. The maximum amount of financial compensation is €780 per year per patient.

In January-March 2023, the Austrian Institute for HTA published Rapid reviews of three health technologies: liposuction for the removal of subcutaneous (large) lipomas, biomarkers in Parkinson's disease, and the use of telepathology in intraoperative frozen section examination.

In December 2023, the Government, Danish Regions, and Municipalities (KL) signed an agreement providing 500 million DKK from 2023 to 2028 to promote the spread of digital treatment services. This will include technologies for home monitoring and targeted control for patients with chronic diseases (such as diabetes, COPD, and heart failure), thus reducing the number of physical check-ups and preventing unnecessary hospitalizations.

In late October 2023, the UK Government announced £100 million funding for the “AI Life Sciences Accelerator Mission”. The Mission will advance and expand the use of AI in life sciences and tackle the country’s major health challenges outlined by Life Sciences Vision.

In November 2023, the Danish Regions announced the launch of a national telemedicine solution for patients with severe chronic obstructive pulmonary disease (COPD). The telemedicine platform Telma, developed by regions and municipalities, comprises a software application for patients connected to devices measuring patients' clinical parameters (such as blood oxygen), which clinicians then assess remotely.

n the period of April-May 2023, the Galician Agency for Health Technology Assessment (AVALIA-T) initiated the five health technology assessments referred to IVD, nephrology and urology, obstetrics and gynecology, pulmonary and airways as well as surgical procedures technology groups. The assessments on stereotactic virtual navigation system for percutaneous puncture as well as tumor ablation and invasive telemonitoring of pulmonary pressure in patients with heart failure were released.

On March 31, 2023, the Ministry of Health and Prevention published the Decree in the Official Journal of the French Republic that defines an application process for the early coverage of digital medical devices for therapeutic purposes and medical telemonitoring by health insurance.

In February 2023, the Scottish Health Technology Group, SHTG, released three MedTech-related assessments: selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma, Feeling Good app, store-and-forward teledermatology for triage of primary care referrals.

On January 25, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another two completed projects. The projects relate to the improvement of the management of peripheral arterial occlusive disease (PAD) patients and the aftercare of pediatric patients suffering from chronic pain.

In the fourth quarter of 2022, Health Technology Wales published three MedTech-related guidance (Left atrial appendage occlusion in patients with atrial fibrillation, continuous topical oxygen therapy, and virtual reality distraction therapy). Four Topic Exploration Reports were released as well (virtual wards, genetic testing for prostate cancer, autofluorescence imaging, and geniculate artery embolization); however, Health Technology Wales decided not to proceed with complete appraisals on these topics.